Pancreatic Cancer
Pancreatic cancer is a highly lethal malignancy that usually presents as an advanced disease. It is characterized by resistance to standard chemotherapy, and immune-based therapies, such as checkpoint suppression, are also largely ineffective, so pancreatic cancer is classified as immunologically "cold tumors". Alfa Cytology provides high-quality pancreatic cancer vaccine development services.
Introduction to Pancreatic Cancer
Several factors make pancreatic cancer difficult to treat. First, the lack of early diagnostic markers or discernible symptoms often leads to the diagnosis of locally advanced or metastatic disease at the time of visit. Second, therapy options for pancreatic cancer are limited extremely, further exacerbating the poor prognosis. The immunotherapy of pancreatic cancer vaccine has advantages to some theoretical degree.
Utilization of Vaccine in Pancreatic Cancer
Pancreatic cancer is characterized by inter-tumor and intra-tumor heterogeneity, especially in terms of inherited genetic changes and tumor microenvironment. The cancer vaccine has become a promising alternative to pancreatic cancer therapy due to its many advantages.
- Multiple Targeting
- Wide Therapeutic Window
- Induction of Long-Lasting Immune Memory
- Minimal Non-Specific Effects
- Low Toxicity
New Pancreatic Cancer Vaccine
Pancreatic cancer is an aggressive and malignant tumor with a very high mortality rate. Traditional therapy strategies for pancreatic cancer have often met with resistance, highlighting the need for personalized precision therapy. Tumor-targeting vaccines can prevent tumor cells from escaping immune surveillance and activate the immune system to destroy cancer cells, which is an important breakthrough in the therapy of pancreatic cancer.
Personalized mRNA Pancreatic Cancer Vaccine
In addition to inter-tumor heterogeneity, there is also more evidence for intra-tumor heterogeneity in pancreatic cancer. It is largely responsible for adaptive resistance to cancer therapy, underscoring the importance of personalized precision therapy. Cancer vaccines have several advantages over traditional therapies. Messenger RNA (mRNA) based vaccines offer a technological and conceptual advance in personalized precision therapy.
- Generation of natural protein products
- Induction of both innate and adaptive immunities
- High safety in practice
- Convenience and low cost of preparation
Pancreatic Cancer Vaccines Targeting the Tumor Microenvironment (TME)
TME plays an important role in the metastasis and progression of pancreatic cancer. Pancreatic TME is characterized by a fibrous inflammatory and immunosuppressive matrix. The main goal of vaccination is to enhance the ability of tumor-specific T cells and force the immune stimulant to be delivered directly to the TME. The key to a successful vaccine is both the killing of tumor cells and the proper use of adjuvants.
It is worth mentioning that gastrin stimulates the growth of pancreatic cancer in two ways, paracrine and autocrine. Inhibiting the cancer-promoting effects of gastrin in pancreatic cancer can reduce metastasis by altering the TME and reducing the pathway that activates epithelial-mesenchymal transformation (EMT). Based on this, there are pancreatic cancer vaccine research against gastrin. Besides, combined with PD-1 immune or checkpoint antibodies may improve pancreatic cancer survival by reducing tumor growth and metastasis formation.
Our Service
Depending on research needs, Alfa Cytology provides diversified pancreatic cancer vaccine development services based on different targets or methods.
Antigen-Based
Nucleic Acid-Based
Alfa Cytology is committed to the research and development of cancer vaccines, from the discovery of cancer antigens, and the development of different types of vaccines, to vaccine research for different cancer types, providing one-stop services. If you are interested in our service, please contact us.